ABECB

(redirected from acute bacterial exacerbations of chronic bronchitis)
AcronymDefinition
ABECBacute bacterial exacerbations of chronic bronchitis
References in periodicals archive ?
Multicenter, randomized study comparing efficacy and safety of oral levofloxacin and cefaclor in treatment of acute bacterial exacerbations of chronic bronchitis.
Antibiotic therapy for community-acquired bacterial RTIs, including acute bacterial sinusitis (ABS), acute bacterial exacerbations of chronic bronchitis (ABECB), and community-acquired pneumonia (CAP), is typically empiric and requires careful evaluation of patients and antibiotics.
A panel of primary care physicians and specialists convened by the Canadian Thoracic Society (CTS) reviewed nearly 400 published articles on acute bacterial exacerbations of chronic bronchitis, including evidence-based reviews such as the Cochrane Database.
FACTIVE([R]) (gemifloxacin mesylate) tablets is an antibiotic FDA-approved for the treatment of acute bacterial exacerbations of chronic bronchitis and community-acquired pneumonia of mild to moderate severity.
Oscient first launched FACTIVE for the seven-day treatment of CAP and the five-day treatment of acute bacterial exacerbations of chronic bronchitis (AECB) in the fall of 2004.
for the seven-day treatment of mild to moderate CAP, including CAP caused by multi-drug resistant Streptococcus pneumoniae, and the five-day treatment of acute bacterial exacerbations of chronic bronchitis.
FACTIVE(R) (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and community-acquired pneumonia of mild to moderate severity.
Full browser ?